The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices will convene July 22 to discuss a pair of recent issues related to COVID-19 vaccines.

The agenda released ahead of the meeting includes discussion of the reported risk of Guillain-Barré Syndrome from the Johnson & Johnson vaccine, which recently prompted the Food and Drug Administration to update its vaccine recipient and vaccination provider fact sheets.

The committee will also discuss clinical considerations for additional vaccine doses in immunocompromised individuals; this represents the first formal consideration of boosters for individuals who have already completed a full dose regimen of the COVID-19 vaccines.

Related News Articles

Headline
Pfizer Inc. today announced that the federal government has agreed to purchase an additional 200 million doses of its COVID-19 vaccine. The deal raises the…
Headline
The Health Resources and Services Administration yesterday awarded rural health clinics about $49,500 each for outreach to increase COVID-19 vaccinations in…
Perspective
The widespread belief that we have completely turned the corner in our fight against COVID-19 does not apply equally to all parts of the country. In many…
Headline
The AHA Board of Trustees yesterday adopted a policy statement that supports hospitals and health systems that adopt mandatory COVID-19 vaccination…
Headline
The AHA, American Medical Association and American Nurses Association today released a public service announcement urging the American public to “ask questions…
Headline
Pfizer today said its COVID-19 vaccine will receive a priority review from the Food and Drug Administration, indicating that Pfizer has completed its…